Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.

Shaina TempletonMichael MoserChris WallJohn ShawHaji ChalchalYigan LuoAdnan ZaidiShahid Ahmed

Published in: Journal of gastrointestinal cancer (2021)

The current study suggests that patients with borderline resectable pancreatic cancer who received FOLFIRINOX tend to have better outcomes. Future studies are warranted to establish a preferred systemic therapy for patients with borderline resectable pancreatic cancer.

Keyphrases

locally advanced
rectal cancer
squamous cell carcinoma
radiation therapy
liver metastases
type diabetes
adipose tissue
case control
insulin resistance
weight loss